Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week studyTsutomu Takeuchi, Hisashi Yamanaka, Yoshiya Tanaka et al.|Lara D. Veeken|2011Cited by 89
Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trialsYoshiya Tanaka, Hideto Kameda, Toshiya Takahashi et al.|Modern Rheumatology|2021Cited by 5
Safety and effectiveness of sarilumab in Japanese patients with rheumatoid arthritis refractory to previous treatments: An interim analysis of a post-marketing surveillanceHideto Kameda, Yoshiya Tanaka, Katsuhisa Suzuki et al.|Modern Rheumatology|2023Cited by 4
Safety of sarilumab in a Japanese population with rheumatoid arthritis by age group: Data from an interim analysis of a postmarketing surveillance studyHideto Kameda, Yoshiya Tanaka, Sadatomo Tasaka et al.|Modern Rheumatology|2024Cited by 4
Efficacy and safety of sarilumab in patients with rheumatoid arthritis stratified by age (&lt;65 and ≥65 years): A <i>post hoc</i> analysis of Japanese Phase 3 clinical trialsYoshiya Tanaka, Hideto Kameda, Toshiya Takahashi et al.|Modern Rheumatology|2024Cited by 4